Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Smith & Nephew plc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.81 (market cap $45.04M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 246.4× KraneShares Hang Seng TECH Index ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Smith & Nephew plc for 121 Days on average.
| KTEC | SNN | |
|---|---|---|
Market Cap | $45.04M | $11.10B |
Volume | 29,043 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $37.17 |
52-Week Low | $11.41 | $26.42 |
Typical Hold Time | 44 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.81, up 1.99% with bearish technical signals from moving averages. The company reported $120.04M revenue in 2016 with improving net margin (-0.59% vs -4.88% in 2015) and positive operating cash flow of $5.81M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC shows operational improvement but faces profitability challenges with negative net income. The stock's technical weakness and volatile earnings history suggest cautious approach. Upside depends on sustained revenue growth and margin expansion in competitive tech ETF space.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
